stoxline Quote Chart Rank Option Currency Glossary
  
Eyenovia, Inc. (EYEN)
15.82  5.26 (49.81%)    07-02 16:00
Open: 10.7
High: 17.085
Volume: 4,562,234
  
Pre. Close: 10.56
Low: 10.7
Market Cap: 81(M)
Technical analysis
2025-07-15 3:16:55 PM
Short term     
Mid term     
Targets 6-month :  19.95 1-year :  23.3
Resists First :  17.08 Second :  19.95
Pivot price 10.51
Supports First :  7.83 Second :  2.1
MAs MA(5) :  11.9 MA(20) :  8.87
MA(100) :  3 MA(250) :  21.93
MACD MACD :  2.5 Signal :  2.3
%K %D K(14,3) :  64.2 D(3) :  61.9
RSI RSI(14): 64.1
52-week High :  124.8 Low :  0.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ EYEN ] has closed below upper band by 27.1%. Bollinger Bands are 366.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.83 - 12.92 12.92 - 12.99
Low: 10.26 - 10.34 10.34 - 10.4
Close: 12.47 - 12.61 12.61 - 12.73
Company Description

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Headline News

Mon, 30 Jun 2025
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement - Yahoo Finance

Wed, 25 Jun 2025
Eyenovia Makes History: First US Public Company to Launch Institutional Crypto Validator on Hyperliquid - Stock Titan

Mon, 23 Jun 2025
Eyenovia Announces Closing of $50 Million Private - GlobeNewswire

Mon, 23 Jun 2025
Eyenovia Makes Bold Crypto Move: $50M Raise Powers 1M HYPE Token Buy While FDA Device Advances - Stock Titan

Wed, 18 Jun 2025
Eyenovia Secures Major Win: 33% Lower Interest Rate and Top Crypto Advisor Join Forces - Stock Titan

Tue, 17 Jun 2025
Eyenovia stock soars after $50 million investment for cryptocurrency strategy By Investing.com - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 2.63e+006 (%)
Held by Institutions 0.4 (%)
Shares Short 59 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.913e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 588.9 %
Return on Equity (ttm) -117.8 %
Qtrly Rev. Growth 67060 %
Gross Profit (p.s.) 194.8
Sales Per Share 0
EBITDA (p.s.) -6.52e+006
Qtrly Earnings Growth -42.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -3.86
Stock Dividends
Dividend 0
Forward Dividend 114160
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android